Aurinia Pharmaceuticals Inc
AUPH Healthcare Biotechnology
Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024. In the quarter to June 2026, revenue grew 18.9%, EPS grew 81.3%, free cash flow grew 19.1% and total debt fell 25.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow AUPH
Aurinia Pharmaceuticals Inc (AUPH) Altman Z-score
Aurinia Pharmaceuticals Inc's Altman Z-score for fiscal 2025 is 7.86, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 7.86 | 4.65 |
| FY2024 | 3.20 | 0.49 |
| FY2023 | 2.71 | (0.84) |
| FY2022 | 3.56 | (22.15) |
| FY2021 | 25.70 | 9.44 |
| FY2020 | 16.26 | (26.05) |
| FY2019 | 42.31 | 36.11 |
| FY2018 | 6.20 | (0.12) |
| FY2017 | 6.32 | 11.72 |
| FY2016 | −5.40 | 3.69 |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.53 | — | 0.64 | |
| Retained earnings / total assets | (0.86) | — | −1.21 | |
| EBIT / total assets | 0.15 | — | 0.50 | |
| Market value of equity / total liabilities | 12.59 | — | 7.55 | |
| Sales / total assets | 0.38 | — | 0.38 | |
| Altman Z-score | Safe zone | 7.86 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 5.27 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| CLDX Celldex Therapeutics, Inc. compare | 14.4× |
| AUPH Aurinia Pharmaceuticals Inc | 7.9× |
| VRDN Viridian Therapeutics, Inc. compare | 6.7× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 5.2× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 0.4× |
| FTRE Fortrea Holdings Inc. compare | −0.3× |
| NVAX Novavax, Inc. compare | −2.2× |
| SLS SELLAS Life Sciences Group, Inc. compare | −16.8× |
| IRON Disc Medicine, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets